ReviewJournal of clinical medicine2022
Urinary Exosomal MicroRNAs as Biomarkers for Obesity-Associated Chronic Kidney Disease.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 14 citations in OpenAlex.
- Circulating miRNAs in pediatric obesity: a single-center exploratory study of their potential association with renal function.Frontiers in molecular biosciences · 2026Article
- Robustness of urinary extracellular vesicle-derived MiRNA profiles over multiple days and the impact of urine concentration.Scientific reports · 2025Article
- Noninvasive Urinary Biomarkers for Obesity-Related Metabolic Diseases: Diagnostic Applications and Future Directions.Biomolecules · 2025Review
- Obesity-Related Chronic Kidney Disease: From Diagnosis to Treatment.Diagnostics (Basel, Switzerland) · 2025Review
- Advancements in the non-invasive diagnosis of renal fibrosis.Frontiers in medicine · 2025Review
- Urinary exosomes as promising biomarkers for early kidney disease detection.American journal of clinical and experimental urology · 2025Review
- The Kidney in Obesity: Current Evidence, Perspectives and Controversies.Current obesity reports · 2024Review
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Integrated miRNA-mRNA Analysis Reveals Critical miRNAs and Targets in Diet-Induced Obesity-Related Glomerulopathy.International journal of molecular sciences · 2024Article
- Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in prediabetic mice.American journal of physiology. Cell physiology · 2024Article
- Current and Novel Biomarkers of Progression Risk in Children with Chronic Kidney Disease.Nephron · 2024Review
- Childhood obesity, metabolic syndrome, and oxidative stress: microRNAs go on stage.Reviews in endocrine & metabolic disorders · 2023Review
- Nanomedicines for the management of diabetic nephropathy: present progress and prospects.Frontiers in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The early detection of chronic kidney disease (CKD) is key to reducing the burden of disease and rising costs of care. This need has spurred interest in finding new biomarkers for CKD. Ideal bi-omarkers for CKD should be: easy to measure; stable; reliably detected, even when interfering substances are present; site-specific based on the type of injury (tubules vs. glomeruli); and its changes in concentration should correlate with disease risk or outcome. Currently, no single can-didate biomarker fulfills these criteria effectively, and the mechanisms underlying kidney fibrosis are not fully understood; however, there is growing evidence in support of microRNA-mediated pro-cesses. Specifically, urinary exosomal microRNAs may serve as biomarkers for kidney fibrosis. In-creasing incidences of obesity and the recognition of obesity-associated CKD have increased interest in the interplay of obesity and CKD. In this review, we provide: (1) an overview of the current scope of CKD biomarkers within obese individuals to elucidate the genetic pathways unique to obesi-ty-related CKD; (2) a review of microRNA expression in obese individuals with kidney fibrosis in the presence of comorbidities, such as diabetes mellitus and hypertension; (3) a review of thera-peutic processes, such as diet and exercise, that may influence miR-expression in obesity-associated CKD; (4) a review of the technical aspects of urinary exosome isolation; and (5) future areas of research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.